Skip to main content

Advertisement

Log in

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4ALK Fusion Gene

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small-cell lung cancers (NSCLCs). We screened for EML4–ALK fusion genes and examined the clinicopathological and genetic characteristics of fusion-harboring NSCLC tumors.

Methods

We examined 313 NSCLC samples from patients who underwent resection at our hospital between May 2001 and July 2005. We screened for the fusion genes using reverse-transcription polymerase chain reaction (RT-PCR) assay and confirmed the results with direct sequencing. We also examined mutations in the epidermal growth factor receptor (EGFR), KRAS, and ERBB2 genes.

Results

Five EML4–ALK fusion genes were detected (four from 111 female samples and one from 202 male samples; 1.6% overall). All five genes were found in adenocarcinomas and accounted for 2.4% of the 211 adenocarcinoma samples. One EML4–ALK fusion was variant 1, and two were variant 3. In addition, we also found two new fusion variants. Patients with fusion-positive tumors were nonsmokers or light smokers. Among the 211 adenocarcinomas, mutations in EGFR, KRAS, and ERBB2 were detected in 105, 29, and 7 tumors, respectively. Interestingly, all of the fusion-positive NSCLCs had no mutations within these genes.

Conclusions

EML4–ALK fusion genes were observed predominantly in adenocarcinomas, in female or nonsmoking populations. Additionally, the EML4–ALK fusions were mutually exclusive with mutations in the EGFR, KRAS, and ERBB2 genes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  2. Lee DH, Han JY, Yu SY, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol. 2006;1(9):965–71.

    Article  PubMed  Google Scholar 

  3. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 2008;98(5):907–14.

    Article  CAS  PubMed  Google Scholar 

  4. Qin BM, Chen X, Zhu JD, Pei DQ. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res. 2005;15(3):212–7.

    Article  CAS  PubMed  Google Scholar 

  5. Pao W, Miller V, Zakowski M, et al. EGF receptor mutations are common in lung cancers from “never-smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306–11.

    Article  CAS  PubMed  Google Scholar 

  6. Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg. 2008;56(3):97–103.

    Article  PubMed  Google Scholar 

  7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  8. Mitudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817–24.

    Article  Google Scholar 

  9. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857–65.

    Article  CAS  PubMed  Google Scholar 

  10. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10(24):8195–203.

    Article  CAS  PubMed  Google Scholar 

  11. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11(16):5876–85.

    Article  Google Scholar 

  12. Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11(12):4289–94.

    Article  CAS  PubMed  Google Scholar 

  13. Lee DH, Han JY, Yu SY, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol. 2006;1(9):965–71.

    Article  PubMed  Google Scholar 

  14. Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland of China. J Thorac Oncol. 2007;2(5):430–9.

    Article  PubMed  Google Scholar 

  15. Chang CH, Chen KY, Young-Xu Y, et al. The safety and efficiency of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer. 2008;62(2):242–52.

    Article  PubMed  Google Scholar 

  16. Haringhuizen A, van Tinteren H, Vaessen HF, Bass P, van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol. 2004;15(5):786–92.

    Article  CAS  PubMed  Google Scholar 

  17. Byrne BJ, Garst J. Epidermal growth factor receptor inhibitions and their role in non-small-cell lung cancer. Curr Oncol Rep. 2005;7(4):241–7.

    Article  CAS  PubMed  Google Scholar 

  18. Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother. 2005;6(6):985–93.

    Article  CAS  PubMed  Google Scholar 

  19. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22(3):561–73.

    Article  CAS  PubMed  Google Scholar 

  20. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer. 2006;54(2):193–9.

    Article  PubMed  Google Scholar 

  21. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR mutations in non-small cell lung cancer. J Thorac Oncol. 2006;1(3):231–9.

    PubMed  Google Scholar 

  22. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–23.

    Article  CAS  PubMed  Google Scholar 

  23. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–20.

    Article  CAS  PubMed  Google Scholar 

  24. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.

    Article  CAS  PubMed  Google Scholar 

  25. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008;68(13):4971–6.

    Article  CAS  PubMed  Google Scholar 

  26. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–83.

    Article  CAS  PubMed  Google Scholar 

  27. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618–24.

    Article  CAS  PubMed  Google Scholar 

  28. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93(3):355–63.

    Article  CAS  PubMed  Google Scholar 

  29. Sonobe M, Manabe T, Wada H, Tanaka F. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. JMD. 2006;8:351–356.

    CAS  PubMed  Google Scholar 

  30. Fukuyoshi Y, Inoue H, Kita Y, et al. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer. 2008;98(9):1536–9.

    Article  CAS  PubMed  Google Scholar 

  31. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298–302.

    CAS  PubMed  Google Scholar 

  32. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008;61(2):163–9.

    Article  PubMed  Google Scholar 

  33. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13–7.

    Article  PubMed  Google Scholar 

  34. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508–15.

    Article  CAS  PubMed  Google Scholar 

  35. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174(2):661–70.

    Article  CAS  PubMed  Google Scholar 

  36. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–33.

    Article  CAS  PubMed  Google Scholar 

  37. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008;105(50):19893–7.

    Article  CAS  PubMed  Google Scholar 

  38. Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 2006;118(1):180–4.

    Article  CAS  PubMed  Google Scholar 

  39. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589–95.

    Article  CAS  PubMed  Google Scholar 

  40. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumors. Nature. 2004;431(7008):525–6.

    Article  CAS  PubMed  Google Scholar 

  41. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(1):1642–6.

    Article  CAS  PubMed  Google Scholar 

  42. Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutations status in Japanese lung cancer. Int J Cancer. 2006;118(1):180–4.

    Article  CAS  PubMed  Google Scholar 

  43. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T. K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep. 2001;8(4):889–92.

    CAS  PubMed  Google Scholar 

  44. Shibata T, Hanada S, Kokubo A, et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci. 2007;98(7):985–91.

    Article  CAS  PubMed  Google Scholar 

  45. Sonobe M, Nakagawa M, Takenaka K, et al. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2007;95:63–69.

    Article  CAS  PubMed  Google Scholar 

  46. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We thank Ms. Seiko Sakai for excellent secretarial assistance. This project was not supported by any outside funds.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Makoto Sonobe MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takahashi, T., Sonobe, M., Kobayashi, M. et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4ALK Fusion Gene. Ann Surg Oncol 17, 889–897 (2010). https://doi.org/10.1245/s10434-009-0808-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0808-7

Keywords

Navigation